Re: Pharmacogenomic variation of CYP2D6 and the choice of optimal adjuvant endocrine therapy for postmenopausal breast cancer: A modeling analysis

David Gurwitz*, William Newman

*Corresponding author for this work

Research output: Contribution to journalLetterpeer-review

Original languageEnglish
Pages (from-to)1331
Number of pages1
JournalJournal of the National Cancer Institute
Issue number18
StatePublished - Sep 2008

Cite this